{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:08:19Z","timestamp":1774645699351,"version":"3.50.1"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":108,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1002\/jbmr.4280","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T18:22:05Z","timestamp":1616178125000},"page":"625-626","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-8490","authenticated-orcid":false,"given":"Michael P","family":"Whyte","sequence":"first","affiliation":[{"name":"Center for Metabolic Bone Disease and Molecular Research Shriners Hospitals for Children\u2013St. Louis St. Louis MO USA"},{"name":"Division of Bone and Mineral Diseases, Department of Internal Medicine Washington University School of Medicine St. Louis MO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"2024012713491495500_jbmr4280-bib-0001","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res."},{"key":"2024012713491495500_jbmr4280-bib-0002","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s00198-016-3702-8","article-title":"Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment","volume":"12","author":"Ovejero","year":"2016","journal-title":"Osteoporos Int."},{"issue":"Suppl 1","key":"2024012713491495500_jbmr4280-bib-0003","first-page":"75","article-title":"First report of burosumab (anti-FGF23 monoclonal antibody) for rickets complicating HRAS-associated cutaneous skeletal hypophosphatemia syndrome (abstract)","volume":"34","author":"Smith","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2024012713491495500_jbmr4280-bib-0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jbmr.2307","article-title":"PHEX 3'-UTR mutation c.*231A>G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets","volume":"30","author":"Mumm","year":"2015","journal-title":"J Bone Miner Res."},{"key":"2024012713491495500_jbmr4280-bib-0005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/jbmr.3955","article-title":"X-linked hypophosphatemia: uniquely mild disease associated with PHEX 3'-UTR mutation c.*231A>G (a retrospective, case-control study)","volume":"35","author":"Smith","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024012713491495500_jbmr4280-bib-0006","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4280","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4280","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/4\/625\/55456829\/jbmr4280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/4\/625\/55456829\/jbmr4280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:06:57Z","timestamp":1710342417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/4\/625-626\/7499853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":6,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,3,19]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4280","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2021-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}